

Supplementary Data

SUPPLEMENTARY TABLE S1. ADJUSTED PAIRWISE CORRELATION AMONG THREE PLASMA ANALYTES AND TWO HIV-1-RELATED OUTCOMES IN 60 YOUTH^a

<i>Parameter</i>	<i>IL-10</i>	<i>IL-18</i>	<i>Soluble CD30</i>	<i>HIV-1 viral load</i>	<i>CD4⁺ T cell</i>
IL-10	0.765 (<0.0001)	0.284 (0.026)	0.348 (0.009)	0.381 (0.004)	-0.339 (0.011)
IL-18	0.422 (0.002)	0.768 (<0.0001)	0.171 (0.212)	0.269 (0.047)	-0.322 (0.017)
Soluble CD30	0.374 (0.006)	0.293 (0.033)	0.829 (<0.0001)	0.483 (<0.001)	-0.330 (0.014)
HIV-1 viral load	0.523 (<0.0001)	0.371 (0.006)	0.519 (<0.0001)	0.823 (<0.0001)	-0.710 (<0.0001)
CD4 ⁺ T cell	-0.597 (<0.0001)	-0.381 (0.005)	-0.482 (<0.001)	-0.790 (<0.0001)	0.890 (<0.0001)

^aSimilar to results presented in Table 2, each individual is analyzed for two treatment-free visits within the first 3 years of longitudinal follow-up study. Results (Spearman ρ and p value in parentheses) from visit 1 are over the diagonal, after statistical adjustment for race, sex, age, and BMI; adjusted results from visit 2 are below the diagonal; tests between visit 1 and visit 2 are in italics on the diagonal, with further adjustment for the visit interval. The best predictor of HIV-1 viral load within each visit is shown in bold.

SUPPLEMENTARY TABLE S2. PAIRWISE CORRELATION AMONG THREE PLASMA ANALYTES AND TWO HIV-1-RELATED OUTCOMES IN 48 AIDS-FREE YOUTH^a

	<i>IL-10</i>	<i>IL-18</i>	<i>Soluble CD30</i>	<i>HIV-1 viral load</i>	<i>CD4⁺ T cell</i>
IL-10	0.729 (<0.0001)	0.304 (0.036)	0.570 (<0.0001)	0.436 (0.002)	-0.480 (<0.001)
IL-18	0.277 (0.056)	0.720 (<0.0001)	0.374 (0.008)	0.356 (0.013)	-0.380 (0.008)
Soluble CD30	0.483 (<0.001)	0.333 (0.021)	0.856 (<0.0001)	0.762 (<0.0001)	-0.707 (<0.0001)
HIV-1 viral load	0.390 (0.006)	0.314 (0.030)	0.739 (<0.0001)	0.833 (<0.0001)	-0.751 (<0.0001)
CD4 ⁺ T cell	-0.334 (0.020)	-0.336 (0.019)	-0.576 (<0.0001)	-0.748 (<0.0001)	0.871 (<0.0001)

^aAs in Table 2, each individual is analyzed for two treatment-free visits within the first 3 years of longitudinal follow-up study. Those ($n = 18$) with severe immunodeficiency (less than 200 CD4⁺ T cells per μ l of blood) at any visit are excluded. Results (Spearman ρ and p value in parentheses) from visit 1 are over the diagonal; results from visit 2 are below the diagonal; comparison between visit 1 and visit 2 are in italics on the diagonal. The best predictor of HIV-1 viral load within each visit is shown in bold.